Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-a0d64103b1c8a608be4329399bf17c80"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-a0d64103b1c8a608be4329399bf17c80"/>
<resource>
<Composition>
<id value="composition-en-a0d64103b1c8a608be4329399bf17c80"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-a0d64103b1c8a608be4329399bf17c80"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-a0d64103b1c8a608be4329399bf17c80</b></p><a name="composition-en-a0d64103b1c8a608be4329399bf17c80"> </a><a name="hccomposition-en-a0d64103b1c8a608be4329399bf17c80"> </a><a name="composition-en-a0d64103b1c8a608be4329399bf17c80-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1723/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - hyftor</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/23/1723/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpa0d64103b1c8a608be4329399bf17c80"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - hyftor"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Hyftor is and what it is used for</li><li>What you need to know before you use Hyftor</li><li>How to use Hyftor</li><li>Possible side effects</li><li>How to store Hyftor</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What hyftor is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What hyftor is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Hyftor contains the active substance sirolimus, which is a medicine that reduces the activity of the immune system.<br/>In patients with tuberous sclerosis complex a protein that regulates the immune system, m-TOR, is overactive. By blocking the activity of m-TOR, Hyftor regulates cell growth and reduces the number or size of angiofibromas.</p><p>Hyftor is a medicine used to treat adults and children from 6 years of age with angiofibroma on the face resulting from tuberous sclerosis complex. Tuberous sclerosis complex is a rare genetic disease causing non-cancerous tumours to grow in different organs of the body, including the brain and skin. The disease causes facial angiofibromas, non-cancerous lesions (growths) of the skin and mucous membranes (moist body surfaces, such as the lining of the mouth) in the face, in many patients.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take hyftor"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take hyftor"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Hyftor if you are allergic to sirolimus or any of the other ingredients of this medicine (listed in section 6)</p><p>Warnings and precautions<br/>Talk to your doctor before using Hyftor if you have:</p><ul><li>a weakened immune system</li><li>severely reduced liver function</li></ul><p>Avoid contact of Hyftor with the eyes, the lining of the mouth and nose, or wounds. Similarly, it should not be used on irritated skin or skin that is infected or otherwise damaged. In case of accidental contact it is recommended to immediately wash the gel off.</p><p>Avoid exposing skin treated with Hyftor to direct sunlight since it may cause side effects on the skin. This includes both natural and artificial (for example in the solarium) sunlight. Your doctor will advise you about appropriate sun protection, like the use of sunscreen and clothing to cover the skin or wearing headgear. Children Hyftor is not recommended for children under 6 years since the product has not been sufficiently studied in this age group.</p><p>Other medicines and Hyftor Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>Do not apply other medicines to the area of skin treated with Hyftor.</p><p>Pregnancy and breast-feeding Hyftor is not recommended during pregnancy unless your doctor thinks that the benefits of treatment are greater than the risks. There is no information on the use of Hyftor in pregnant women. Women of childbearing potential should use safe contraception during treatment with Hyftor.</p><p>It is not known, whether sirolimus is excreted into human milk after treatment with Hyftor. You and your doctor should made a decision whether to discontinue breast-feeding or to discontinue/abstain from Hyftor therapy taking into account the benefit of breast feeding for your child and the benefit of therapy for you.</p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>Driving and using machines This medicine is not expected to affect the ability to drive or use machines.</p><p>Hyftor contains alcohol This medicine contains 458 mg alcohol (ethanol) in each gram. It may cause a burning sensation when applied to damaged skin.</p></div>
</text>
</section>
<section>
<title value="3. How to take hyftor"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take hyftor"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is Your doctor or pharmacist will show you how much gel you should use.</p><p>About 0.5 cm of the gel strand twice daily is recommended for a lesion of around 7 by 7 cm (50 cm2).</p><p>The maximum recommended dose on the face is:</p><ul><li>children 6 to 11 years: no more than 1 cm gel strand twice daily</li><li>adults and children from 12 years: no more than 1.25 cm gel strand twice daily</li></ul><p>How to apply the gel Apply a thin layer of Hyftor twice daily (morning and evening) to the affected skin area and rub in gently. The application should be done once in the morning and once in the evening before going to bed. Limit the use to skin areas affected by angiofibroma. Do not cover the affected skin after application of Hyftor.</p><p>Wash your hands carefully before and immediately after using the gel to avoid any unintentional spread or ingestion.</p><p>Duration of use Your doctor will tell you how long you should use Hyftor for.</p><p>If you use more Hyftor than you should Hyftor is applied to the skin and absorption into the body is minimal. This makes overdose very unlikely. If you apply too much gel to a lesion, carefully wipe off the excess gel with a paper towel and throw away the towel.</p><p>If you or anybody else accidentally swallows some gel, contact your doctor immediately.</p><p>If you forget to use Hyftor If you forget to use the medicine in the morning, apply the gel as soon as you remember immediately before your meal in the evening of the same day. After your meal in the evening, only administer Hyftor at bedtime on that day. If you forget to use the medicine at bedtime, skip that dose. Do not apply more gel to make up for a missed dose.</p><p>If you stop using Hyftor Your doctor will tell you how long you should use Hyftor and when you can stop treatment. Do not stop using it without consulting your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>dry skin</li><li>itching skin</li><li>acne</li><li>irritation at the application site, such as reddening, burning stinging, itching, swelling and/or numbness</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>bleeding at application site</li><li>abnormal sensation, including at the application site, such as numbness, prickling, tingling and itchiness</li><li>application site swelling</li><li>eczema characterised by changes that occur when skin becomes abnormally dry, red, itchy and cracked</li><li>dermal cyst (a cyst containing solid tissue or structures such as hair)</li><li>rash, itchy rash</li><li>peeling of skin</li><li>skin irritation</li><li>reddening</li><li>bleeding of the skin</li><li>dermatitis (inflammation of the skin), including contact dermatitis (inflammation of the skin after contact with the medicine), acneiform dermatitis (inflammation of the skin with small acne-like bumps), seborrhoeic dermatitis (skin condition affecting the head with scaly and red skin), solar dermatitis (inflammation of the skin after exposure to sunlight)</li><li>dry, hard and scaly skin</li><li>hives</li><li>nodules</li><li>boils</li><li>tinea versicolour (a fungal infection of the skin)</li><li>inflammation of the lining of the mouth</li><li>increased sensitivity to light</li><li>reddening of the eyelid</li><li>red eye</li><li>eye irritation</li><li>conjunctivitis (redness and discomfort in the eye)</li><li>inflammation of hair follicles</li><li>sensations like numbness, tingling and pins and needles</li><li>nasal discomfort</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store hyftor"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store hyftor"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the tube after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 C 8 C). Store in the original tube in order to protect from light. Keep away from fire.</p><p>Throw away the tube and any remaining gel 4 weeks after opening.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Hyftor contains</p><ul><li>The active substance is sirolimus. Each gram of gel contains 2 mg of sirolimus</li><li>The other ingredients are carbomer, anhydrous ethanol, trolamine and purified water (see section 2 Hyftor contains alcohol ).</li></ul><p>What Hyftor looks like and contents of the pack Hyftor is a transparent, colourless gel. It is supplied in an aluminium tube containing 10 g of gel.</p><p>Pack size: 1 tube</p><p>Marketing Authorisation Holder Plusultra pharma GmbH Fritz-Vomfelde-Str. 40547 D sseldorf Germany</p><p>Manufacturer MSK Pharmalogistic GmbH.<br/>Donnersbergstra e 4<br/>64646 Heppenheim<br/>Germany</p><p>This leaflet was last revised in</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>. There are also links to other websites about rare diseases and treatments.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpa0d64103b1c8a608be4329399bf17c80"/>
<resource>
<MedicinalProductDefinition>
<id value="mpa0d64103b1c8a608be4329399bf17c80"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpa0d64103b1c8a608be4329399bf17c80"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpa0d64103b1c8a608be4329399bf17c80</b></p><a name="mpa0d64103b1c8a608be4329399bf17c80"> </a><a name="hcmpa0d64103b1c8a608be4329399bf17c80"> </a><a name="mpa0d64103b1c8a608be4329399bf17c80-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1723/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Hyftor 2 mg/g gel</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/23/1723/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Hyftor 2 mg/g gel"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
